Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 8457

Next Previous
X
Search
Drug Profile

MK 8457

Alternative Names: MK-8457

Latest Information Update: 02 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Antihypertensives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypertension; Rheumatoid arthritis

Most Recent Events

  • 30 Apr 2014 Discontinued - Phase-I for Hypertension in USA (PO)
  • 30 Apr 2014 Discontinued - Phase-II for Rheumatoid arthritis (combination therapy) in USA, Australia, Canada, Chile, Colombia, Denmark, France, Germany, Hungary, Japan, Latvia, Lithuania, Moldova, New Zealand, Peru, Poland, South Africa, South Korea, Spain, Taiwan and United Kingdom (PO)
  • 01 Oct 2013 Merck & Co. terminates a phase II trial in Rheumatoid arthritis (combination therapy) in USA, Australia, Colombia, Denmark, France, Greece, Hungary, Italy, New Zealand, Poland, South Africa, South Korea, Spain and United Kingdom (NCT01651936; EudraCT2012-002181-12)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top